Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology
暂无分享,去创建一个
[1] S. Gauthier,et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.
[2] Mark E. Schmidt,et al. Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease. , 2017, Journal of medicinal chemistry.
[3] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[4] Allen F. Brooks,et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. , 2014, ACS chemical neuroscience.
[5] R. Vandenberghe,et al. Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807 , 2016, Molecular imaging.
[6] C. Hock,et al. ELISA-Quantitation of Phosphorylated Tau Protein in the Alzheimer’s Disease Brain , 1999, European Neurology.
[7] Kazuhiko Yanai,et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.
[8] Kazuhiko Yanai,et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.
[9] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[10] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[11] Vincent Doré,et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[12] M. Lubberink,et al. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[13] Patrick R. Hof,et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.
[14] Bradford C. Dickerson,et al. Tau PET imaging in aging and early Alzheimer's disease , 2015 .
[15] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[16] Keith A. Johnson,et al. Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects , 2017, The Journal of Nuclear Medicine.
[17] H. Arai,et al. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[18] D. Moechars,et al. Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. , 2015, Journal of medicinal chemistry.
[19] H. Arai,et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[20] Gunnar Antoni,et al. Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue , 2015, Acta neuropathologica communications.
[21] Virginia M. Y. Lee,et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.
[22] A. Fagan,et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.
[23] Jans H. Alzate-Morales,et al. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[24] Lin Xie,et al. Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.
[25] Hiroshi Watabe,et al. Biomathematical screening of amyloid radiotracers with clinical usefulness index , 2017, Alzheimer's & dementia.
[26] Graham Lappin,et al. The phase 0 microdosing concept. , 2006, British journal of clinical pharmacology.
[27] B. Ghetti,et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains , 2017, Alzheimer's Research & Therapy.
[28] D. Fourney. Commentary , 2011, Evidence-based spine-care journal.
[29] K. Togashi,et al. (18)F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. , 2012, ACS medicinal chemistry letters.
[30] Y. Tsuda,et al. Stereoselectivity and enantiomer-enantiomer interactions in the binding of ibuprofen to human serum albumin. , 1997, Chirality.
[31] T. Kudo,et al. Quantitative analysis of neurofilament proteins in Alzheimer brain by enzyme linked immunosorbent assay system , 1999, Psychiatry and clinical neurosciences.
[32] J. Hooker,et al. A Philosophy for CNS Radiotracer Design , 2014, Accounts of chemical research.
[33] W. Honer,et al. Tau Proteins in the Temporal and Frontal Cortices in Patients With Vascular Dementia , 2015, Journal of neuropathology and experimental neurology.
[34] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[35] W. Jagust,et al. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351 , 2016, PloS one.
[36] R. Caselli,et al. A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor , 2017, Journal of neuropathology and experimental neurology.
[37] H. Watabe,et al. Title: Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand Short running title: Prediction of SUVR for amyloid PET probe Authors: , 2017 .
[38] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[39] H. Watabe,et al. Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain. , 2015, Nuclear medicine and biology.
[40] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[41] Talakad G. Lohith,et al. Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.
[42] Denis Guilloteau,et al. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. , 2013, Journal of Alzheimer's disease : JAD.
[43] N. Okamura,et al. Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer , 2016, Molecular Imaging and Biology.
[44] Kazuhiko Yanai,et al. 18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease , 2011 .
[45] Kazuhiko Yanai,et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[46] Gunnar Antoni,et al. Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology , 2016, The Journal of Nuclear Medicine.
[47] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[48] In vivo quantification of neurofibrillary tangles with [18F]MK-6240 , 2018, Alzheimer's Research & Therapy.
[49] H. Arai,et al. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.
[50] Michael Brady,et al. A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development , 2009, Journal of Nuclear Medicine.